Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core High Dividend ETF (HDV) vs Heron Therapeutics Inc (HRTX) Price & Performance

iShares Core High Dividend ETFTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

iShares Core High Dividend ETF vs Heron Therapeutics Inc — how do they compare? iShares Core High Dividend ETF trades at $29.08, while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HDVHRTX
52-Week High
$29.14$1.49
52-Week Low
$23.64$0.32
Market Cap
$63.41M
Sector
Health
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core High Dividend ETF

HDV trades at $28.78, up 0.21% with a bullish technical signal. It yields approximately 3.1% from dividends, with recent payouts in June and July 2026. The ETF focuses on high-quality U.S. large-cap dividend stocks, outperforming the S&P 500 year-to-date by 9 percentage points. News highlights its appeal for retirement income and institutional buying, such as 180 Wealth Advisors increasing its stake by 386.2% in Q2 2026.

The outlook is positive due to strong dividend sustainability and defensive sector weighting, but risks include interest rate sensitivity and concentrated holdings. Analysts favor HDV for income-focused portfolios, citing its quality screening and lower volatility.

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core High Dividend ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.

Read more on HDV

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX